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Summary One hundred and forty-five patients with limited stage small cell lung cancer were included in a
randomized trial to evaluate the effect of chemotherapy with or without chest irradiation. Seventy-six patients
were allotted chemotherapy alone while 69 patients received the same chemotherapy plus radiotherapy, 40Gy
in split-course, administered in weeks 6 and 10 after the initiation of chemotherapy. The chemotherapy
consisted of lomustine, cyclophosphamide, vincristine and methotrexate. Patients treated with chemotherapy
alone survived for a median of 52 weeks compared to 44 weeks in patients receiving the combined regimen
(P=0.055). After exclusion of five early deaths and one patient refusing the irradiation plus 14 completely
resected patients, the remaining 65 patients receiving chemotherapy alone and the 60 patients treated with
chemotherapy plus radiotherapy were included in a new analysis. The difference in survival duration which
could be ascribed to treatment with or without chest irradiation thereby diminished (P=0.24). Eighteen
months' disease-free survival was obtained in 9.2% of the 65 patients and in 9.8% of the 60 patients. The
complete remission rates were 37% and 46%, respectively, (P=0.33) and the median durations of complete
remission were 40 weeks and 52 weeks (P=0.67). Treatment failure of the primary tumour occurred in 85%
of patients treated with chemotherapy alone in contrast to 61% of patients receiving the combined regimen
(P=0.005). Seventy-nine of these patients underwent autopsy at which no residual chest disease was observed
in 17% and 37%, respectively (P=0.045). The combined regimen was more toxic than chemotherapy alone
resulting in significantly greater dose reductions and more pronounced thrombocytopenia. Lung and
pericardial fibrosis was responsible for four deaths among the complete responders in the radiotherapy group.
The combined regimen thus tended to be more efficacious with respect to tumour control at the expense,
however, of increased toxicity which per se, eliminated a potential improvement of the overall therapeutical
results.
In contrast to the other main histologic types of
lung cancer small cell carcinoma (SCC) is generally
non-resectable but highly sensitive to both irradiation
and chemotherapy. Irradiation was the main treat-
ment modality of SCC before the introduction of
chemotherapy. In the early seventies various com-
bination chemotherapy regimens were developed
resulting in prolongation of the survival duration
and in a significant, although minute, fraction of
disease-free long-term survivors (Hansen et al., 1980;
Morstyn et al., 1984). At many centres radiotherapy
was maintained as a part of the treatment at
least in patients with disease confined to well
defined radiation portals. Whether such combined
therapy provides advantages compared to chemo-
therapy alone has been debated for more than a
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decade and a definite role of chest irradiation in
the treatment of SCC has not yet been established
(Morstyn et al., 1984; Bleehen et al., 1983; Tobias,
1985; Byhardt & Cox, 1983; Cohen, 1983). The
combined modality treatment strategy can be
justified by a reduced frequency of chest relapse in
irradiated patients, and by results from uncontrolled
studies suggesting prolonged survival and more long-
term survivors (Byhardt & Cox, 1983). In contrast
a strategy based on chemotherapy alone is sup-
ported by preliminary results of randomized trials
in which the combined regimens did not result in
significant advantages in the median survival figures
but only additional toxicity, often enhanced by the
chemotherapy (Cohen, 1983).
The problem of how best to treat limited stage
SCC has not diminished since the present
prospective randomized study on chemotherapy
with or without chest irradiation was initiated in
1976 (Hansen et al., 1979). The final results of the
trial are now available with 5-year follow-up. This
is an unusually long period before publication of
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results from trials on SCC but not disadvantageous
as it enables an analysis of overall as well as long-
term survival based on complete observations
rather than estimates.
Materials and methods
All patients with SCC referred to the Finsen
Institute or Bispebjerg Hospital from May 1976 to
January 1979 were included in the trial provided (i)
the diagnosis of SCC was histologically or
cytologically satisfied the WHO criteria (The World
Health Organisation, 1981); (ii) the patient was
aged 70 years or less; (iii) the patient had no
previous cancer except primary skin tumours
(excluding melanomas); (iv) that no chemo- or
radiotheraphy had been given; and (v) that
informed consent was obtained.
Prior to initiation of therapy all patients were
evaluated with a routine history and physical
examination, chest X-ray, bilateral bone marrow
examinations (Hirsch et al., 1979) and perito-
neoscopy with liver biopsy (Dombernowsky et al.,
1978). Aspirates or biopsies were obtained when
pleural fluid, enlarged lymph nodes or cutaneous
metastases were observed. Brain scans were only
carried out in patients suspected of metastases.
Complete blood count, serum concentrations of
electrolytes, creatinine, lactic dehydrogenase
(LDH), glutamic oxalo acetic transminase, alkaline
phosphatase and bilirubin were obtained routinely.
Only patients with limited disease were included,
i.e. patients with tumour confined to the primary
site and the regional lymph nodes, including the
mediastinal and the ipsi- and contralateral supra-
clavicular nodes (Qsterlind et al., 1983). Stratifi-
cation according to performance status (WHO
Handbook for Reporting Results of Cancer Treat-
ment, 1979) was carried out prior to the allotment
to chemotherapy with or without chest irradiation.
Treatment
All patients received the same four drug com-
bination chemotherapy consisting of lomustine
70mgm 2 p.o., cyclophosphamide 1000mgm-2 i.V.
and vincristine 1.3mgm 2 i.V. (maximally 2mg)
administered on day 1 followed by methotrexate
20mgm 2 p.o. on days 15 and 18. This treatment
was repeated every 4 weeks. Vincristine 1.3 mgm 2
was furthermore given on days 8, 15 and 22 in the
first cycle. Doses of chemotherapy were increased
by 33% if the blood counts remained within
normal limits, but were reduced 33% if the WBC
count was between 2 3,000 mm3 or the platelet
count was 75-100,000mm-3. Treatment was
withheld if the WBC count was <2,000mm-3 or
the platelet count was <75,000mm-3, and
reinstituted when the counts rose above these
values.
Irradiation was administered through opposed
antero-posterior portals, including the primary
tumour, both hili, and the mediastinum, shaped to
comprise 1 cm margins of normal lung. The supra-
clavicular lymph nodes were only included if
metastases were suspected. No spinal cord shielding
was used. A 6MV linear accelerator was employed
and all patients were treated at the Finsen Institute.
A total dose of 40Gy was delivered in two 5-day
series, 4Gy per daily fraction on days 43-47 and
days 71-75. The radiotherapy was thus scheduled
to be delivered with the second and third doses of
methotrexate. The radiation portals were adjusted
before the second series according to radiographic
changes of the tumour.
Irradiation as well as chemotherapy was given
under out-patient conditions. The chemotherapy
was continued until progression or for 18 months,
when reevaluation was undertaken, repeating
bronchoscopy, bone marrow examination and
peritoneoscopy with liver biopsy. Patients having
progressive disease received further chemotherapy
with alternative agents if their condition permitted
while irradiation was only instituted on specific
indications such as brain metastases, superior vena
caval syndrome or total atelectasis.
Evaluation ofresults
Duration of survival and survival differences
between the two treatment groups were investigated
by use of the life-table and the log rank methods
(Peto et al., 1977). Test statistics with P<0.05 in a
two-tailed test were regarded as significant.
Two analyses were carried out. First, survival
data on all patients allocated to the two treatment
groups were compared. The second analysis
focussed more specifically on the intention of the
applied treatments and completely resected patients,
and patients dying before day 43 were therefore
excluded. Evaluation of response, relapse, and
toxicity was restricted to the reduced series. It
should be noticed that all resected patients and
most early deaths would be ineligible for response
and occurrence of local relapse, anyway, and that
information on toxicity-related early deaths would
be irrelevant for the comparison of the two
treatment regimens.
The exclusion of patients might result in
imbalances between prognostic features of the two
treatment groups. Aims to reduce the influence
from such imbalances were therefore undertaken
according to guidelines described by Peto et al.
(1977) and Byar (1984). Thus, the patients wereCHEMOTHERAPY+IRRADIATION IN SCC 9
stratified into three groups based on pretreatment
performance status, serum LDH, and sex, and the
survival data were tested again, using the stratified
log rank test. The three variables proved to be
important prognostic factors in a multivariate
analysis including 874 patients (Qsterlind, 1985).
Evaluation of response followed the WHO
criteria (WHO Handbook for Reporting Results of
Cancer Treatment, 1979). All roentgenograms and
clinical charts were evaluated retrospectively to
obtain as uniform and accurate a determination of
response and response duration as possible.
Duration of response was counted from the day
when at least a partial remission was obtained to
reappearance of the disease. In general remissions
were not proven before day 28 because chest X-rays
were only carried out at 4-week intervals. Exclusion
of deaths occurring during the first 42 days
eliminated problems related to response
classification of early deaths. Death in remission
results in incomplete follow-up of the 'real'
response duration. The life table and log rank
methods were therefore employed for the evaluation
of response duration as recommended by the WHO
committee (WHO Handbook for Reporting Results
of Cancer Treatment, 1979; Peto et al., 1977).
Occurrence of brain metastases as the only evidence
of recurrent disease, was not regarded as relapse.
Deaths in partial remission were classified as
progressions on the day of death, as were deaths in
complete remission, if residual primary tumour or
systemic metastases were proven at a subsequent
autopsy. Post mortem examinations were achieved
in 68% of the patients.
Differences in response rates between the
treatment groups were evaluated for statistical
significance by use of the chi square test (Armitage,
1971).
Evaluation of haematologic toxicity was based on
nadir values of the haemoglobin concentration, plus
WBC and platelet counts as observed on a
scheduled day of therapy. Recordings on
intervening days were not routine in all patients
and such data were therefore omitted from this
analysis. The number of doses of cyclophosphamide
and the total cumulated dose m-2 surface-area
were recorded in order to compare dose reductions
undertaken in the two treatment groups. Cyclo-
phosphamide was chosen among the four agents in
the combination because dose adjustments of this
agent, in contrast to lomustine, are not restricted
by a fixed content in mg per capsule, and because
adjustments of this agent almost exclusively depend
on the haematological toxicity. Wilcoxon's rank
sum test (Armitage, 1971) was applied to test for
differences between the two groups, in nadir values,
and in avergae cyclo-phosphamide doses received
by each patient.
Results
A total of 148 patients were included in the trial,
105 at the Finsen Institute and 43 at Bispebjerg
Hospital. One patient was lost to follow-up after
the initial dose and two patients were excluded at
the revision of the histopathological specimens,
leaving 145 eligible patients of whom 76 were
allotted to chemotherapy alone and 69 to chemo-
plus radiotherapy. The diagnosis of SCC was based
on cytology alone in five and four of these patients,
respectively. Survival curves of the two groups of
patients are shown in Figure 1. The difference
between the curves was not significant (P=0.055),
although patients treated with chemotherapy alone
generally survived longer than those receiving the
combined regimen, the median survival being 52
weeks and 44 weeks, respectively.
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Figure 1 Survival of 145 patients with limited SCC
according to whether they were allotted -o
chemotherapy alone ( ; n =76) or chemotherapy
plus irradiation (----, n=69).
Twenty patients were excluded from the
subsequent analyses. Eleven and three patients
treated with chemotherapy alone or chemo- and
radiotherapy, respectively, were excluded because
they underwent a complete resection prior to
inclusion in the trial. One patient, refusing
radiotherapy in spite of initial consent, and 5 early
deaths, all occurring in the group allotted to
irradiation, were also excluded. Three patients with
signs of progressive disease at chest X-ray and one
in whom brain metastases appeared during the first
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6 weeks of chemotherapy all received the scheduled
chest irradiation and remained in the reduced
combined treatment group. Remaining after these
exclusions were 65 patients treated with chemo-
therapy alone and the 60 patients receiving the
combined regimen. Survival curves are shown in
Figure 2. The median survival durations were 50
weeks and 46 weeks, respectively (P=0.24).
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Table I Pretreatment prognostic factors in 125 patients
eligible for evaluation of treatment efficacy. The lower
part of the table includes a retrospective stratification
based on the three factors and median survival durations
observed within the strata
Prognostic Chemotherapy Chemo- plus
factors and alone radiotherapy
strata n=65 n=60
Sex: males 73% 72%
females 27% 28%
Performance
status: 0 35% 37%
1 56% 53%
2 9% 9%
3-4 0% 1%
LDH: normal 62% 54%
elevated 38% 46%
Prognosis:
Good 43% 39%
Intermediate 32% 39%
Bad 25% 23%
Median survival:
Prognosis
Good 60 weeks 54 weeks
Intermediate 48 weeks 44 weeks
Bad 38 weeks 32 weeks
0
Time (years)
Figure 2 Survival of 125 patients eligible for
evaluation of treatment efficacy, 65 patients (
treated with chemotherapy alone and 60 (----) treated
with chemotherapy plus irradiation.
A stratified analysis of the survival data was
carried out in order to reduce confounding
influence from the three main pretreatment
prognostic factors (Table I). The lower half of the
Table includes the distribution of the patients on
prognostic strata and the median survival durations
observed within each stratum. Treatment with
chemotherapy alone was associated with longest
survival duration at all three levels but the effect
was not significant (P=0.53).
Survival beyond. the 18 months for which
chemotherapy was scheduled was observed in 11
patients from each treatment group. Six patients
from each group (9.2% vs. 9.8%) had no evidence
of residual disease at the restaging. Systemic
recurrences later appeared in three and brain
metastases alone in 2 of the 12 disease-free 18
month survivors. No relationship was apparent
between risk of late relapse and type of treatment
(Table II).
Evaluation ofresponse
Sixty patients treated with chemotherapy alone and
57 patients receiving the combined regimen were
evaluable for response. Three and two patients,
respectively, were inevaluable because incomplete
resections were carried out prior to the admission,
and two and one patients, respectively, had no
evaluable lesions on the chest X-ray. Complete
remission of all clinical and radiological signs of
disease was observed in 22 (37%) of the patients
treated with chemotherapy alone, compared to 26
(46%) of those receiving the combined regimen
(P=0.33). Two of the 26 patients had no signs of
response prior to initiation of radiotherapy. Partial
remissions were achieved in 27 patients (45%) and
24 patients (42%), respectively. All 24 patients
responded to chemotherapy before irradiation was
initiated. The overall response rates in the two
treatment groups (82% versus 88%) were not
significantly different (P=0.38).
The response duration analysis included 18
complete responders dying without clinical evidence
of relapse, 5 treated with chemotherapy alone and
13 receiving the combined regimen. One and 6 of
these patients, respectively, had residual or metasta-
tic disease at necropsy (Tables II and III) and were
accordingly regarded as recurrences at the day of
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Table II Outcome of twelve 18-months' disease-free survivors. Survival was counted from
initiation of chemotherapy
Survival Autopsyfindings
Regimen free ofSCC
and no. Sex Outcome (weeks) Systemic Brain
1-1 M Brain metastases * 81 0 +
1-2 M Alcoholic liver cirrhosis * 131 0
1-3 M Recurrent SCC 186 -
1-4 F Cardiac disease * 201 - -
1-5 F Adenocarcinoma in the
contralateral lung * 260 0 0
1-6 M Alive and disease-free 451 - -
2-1 M Radiation lung fibrosis * 84 0 0
2-2 F Radiation lung+
pericardial fibrosis * 89 0 0
2-3 M Recurrent SCC 99 + 0
2-4 M Recurrent SCC 118 + +
2-5 F Brain relapse * 259 0 +
2-6 M Malignant astrocytoma * 281 0 0
Regimen: 1: chemotherapy alone, 2: chemo- plus radiotherapy. Sex: M: male, F: female.
Autopsy findings: 0: no SCC, +: SCC, -: not examined. *: Died in clinical systemic
complete remission.
Table III Causes of death and autopsy findings in 10 complete responders dying without
clinical signs of systemic recurrence while still receiving chemotherpy
Autopsyfindings
Regimen Survival
and no. Sex Cause ofdeath (weeks) Systemic Brain
1-1 M Pneumonia 18 + 0
2-1 F Fungal pneumonia 21 + 0
2-2 M Pneumonia 24 0 -
2-3 M Brain metastases 28 + +
2-4 M Myocardial infarction 30 0 0
2-5 M Radiation pericarditis 48 0 0
2-6 M Brain metastases 49 - -
2-7 F Radiation lung fibrosis 50 + 0
2-8 M Brain metastases 56 + +
2-9 M Brain metastases 58
Regimen: 1: chemotherapy alone, 2: chemo- plus radiotherapy. Sex: M: male, F: female.
Autopsy findings: 0: no SCC, +: SCC, -: not examined.
death. Two patients with clinically verified brain
metastases (Nos. 2-6 and 2-9, Table III) had no
necropsy and were categorized as relapses because
systemic disease was proven post mortem in two
comparable cases (Nos. 2-3 and 2-8). The resulting
life tables of complete and partial remission dur-
ation in the two treatment groups are shown in
Figure 3. The response durations tended to be
longest in patients receiving the combined regimen
but the differences were not significant for complete
(P=0.67) or partial (P=0.58) responders. The
median values were 40 weeks and 46 weeks for the
duration of complete remission and 22 weeks and
26 weeks for partial remissions, corresponding to
patients treated with chemotherapy alone or with
the combined treatment regimen, respectively.
Relapse pattern
Clinical evidence of disease progression was12 K. 0STERLIND et al.
Table IV Clinical disease status at time of death in
patients with evaluable tumours
Chemotherapy Chemotherapy+
alone irradiation
n=60 n=57
No progression ofsystemic disease:
Complete respondersa 5 13
Partial responders 3 7
Progression:
Intrathoracic
recurrence 48 28
Extrathoracic
recurrence only 4 9
aAdditional data on these patients are given in Tables II
and III.
Figure 3 Life table estimates of remission durations
in complete responders (upper curves), 22 treated with
chemotherapy alone ( ) and 26 receiving
chemotherapy plus irradiation (----). The lower
curves show the response duration in partial
responders, 27 patients treated with chemotherapy
alone ( ) and 24 (----) patients receiving
chemotherapy plus irradiation.
achieved in 52 (87%) and 37 (65%) of the 60 and
57 patients who were evaluable for response. Three
(5%) and seven (12%) patients, respectively, had
stable partial tumour remissions at the time of
death. Radiologic evidence of intrathoracic pro-
gression, alone or in combination with occurrence
of distant metastases, was observed in 48 and 28
patients, respectively. Evidence of remaining or
recurrent tumour at chest X-ray was thus present in
51 (85%) and 35 (61%) of the patients at the time
ofdeath (P=0.005) (Table IV).
Thirty-six (60%) and 43 (75%) of the 117
evaluable patients underwent post mortem examin-
ations (Table V). No residual primary tumour was
observed in 10 (28%) of the patients receiving
chemotherapy alone compared to 24 (56%) of the
irradiated patients (P=0.013). Four and 8 of these
patients, respectively, had residual SCC in the
chest, outside the primary lung. Control of chest
disease was thus achieved in 6 (17%) and 16 (37%)
of the patients, respectively (P=0.045).
Table V Postmortem findings in 79 (68%) of the 117 evaluable patients
A: Chemotherapy B: Chemotherapy
alone +irradiation A vs B
n=36 n=43 P
No residual SCC 2 (8)8 (3)0 Only brain metastases 1 (8%) 2 (23%) 0.08
Residual systemic disease 33 33
Sites:
Residual primary tumour 26 (79%) 19 (58%) 0.07
Residual tumour in chest 30 (91%) 27 (82%) 0.3
Liver metastases 23 (70%) 22 (67%) 0.8
Adrenal metastases 9 (27%) 12 (36%) 0.4
Brain metastasesa 11/26 (42%) 14/32 (44%) 0.9
aIncluding the three patients with autopsy findings of SCC confined to the brain.
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Toxicity oftherapy
Fifty of the 60 patients treated with the combined
regimen received both series of irradiation. One
patient refused the second course while 9 patients
died or progressed during the three weeks rest
period.
Equal numbers of chemotherapy courses were
administered in the two treatment groups but dose
reductions were greatest in the irradiated patients.
A median of 7 doses of cyclophosphamide was thus
given to each patient in both groups, the ranges
being 3-17 and 2-19, respectively. The average
dosage of cyclophosphamide was 790mg m-2
dose-1 (range: 500-1050) in patients treated with
chemotherapy alone, and 710mgm-2 dose-1
(range: 360-980) in the irradiated patients
(P=0.05).
Dysphagia for one to two weeks after radio-
therapy was recorded in 44 patients (72%) while
this symptom was not registered in non-irradiated
patients. Roentgenographic signs of pulmonary
fibrosis within the radiation portals were observed
in 26 patients (43%). Respiratory insufficiency and
pericardial effusion (in two patients) were the main
causes of death in 4 complete responders (Tables II
and III), and an emergency pericardiotomy was
carried out in one patient (No. 2-6, Table II) 71
weeks after initiation of the radiotherapy.
The haematologic toxicity observed in the two
treatment groups is summarized in Table VI. The
degree of thrombocytopenia was significantly
greater in the irradiated patients compared to those
receiving chemotherapy alone, while haemoglobin
and leukocyte nadir values did not differ signifi-
cantly between the groups. Nine and 5 patients,
respectively, were hospitalized and treated with i.v.
antibiotics because of febrile episodes during leuko-
penia. Two patients, both receiving the combined
regimen, died at such incidents.
Hospital admissions were undertaken with the
same frequency in the two treatment groups, the
median duration of hospitalization corresponded to
3% of the treatment duration in both groups.
Chemotherapy after relapse.
Fifty of the 52 patients relapsing after treatment
with chemotherapy alone and 30 of the 37 recur-
rences observed in the irradiated group received a
two-agent combination of etoposide 100mgm-2
p.o. for 4 days and doxorubicin 30mgm-2 i.V.,
repeated every 3 weeks. Forty-four and 18 of these
patients were evaluable for response. Objective
remissions were observed in 6 and 2 patients,
respectively, corresponding to a response rate of
13%. Response duration was short with a median of
6 weeks and a range of 5-42 weeks.
Subsequent chemotherapy with investigative
agents in phase II trials were given to 21 and 13
patients from the respective treatment groups. Ten
and five of these patients received vindesine and
partial remissions were observed in 3 and one
patients, respectively, the response duration being 4
to 7 weeks (Qsterlind et al., 1981).
Table VI Haematological toxicity. Proportions of patients experiencing nadir values (on
days when therapy was scheduled) within the signified intervals, at least once in the
treatment
A: Chemotherapy B: Chemotherapy
alone +irradiation A vs. Ba
n=65 n=61 P
Haemoglobin (gdl')
>1I1.0 25% 18%
9.6-11.0 48% 39% 0015
8.1-9.5 20% 36%
<8.0 7% 7%
Leukocytes (IO mm-3)
>3.0 6% 5%
2.0-2.9 17% 11% 0.38
1.0-1.9 49% 54%
< 1.0 28% 30%
Platelets (103mm-3)
. 100 55% 36%
50-99 28% 28% 0.01
0-49 17% 36%
aResult of Wilcoxon's rank sum test.14 K. 0STERLIND et al.
Discussion
The question whether or not thoracic irradiation
adds to the results of chemotherapy in patients with
limited stage SCC has been unanswered for more
than a decade. Data from non-randomized trials
have suggested that there may be some advantages
of combined modality therapy but valid conclusions
generally cannot be drawn from uncontrolled
studies. Within the last five years preliminary data
from randomized trials have been published.
Available information from ongoing trials, were
discussed and evaluated at the First International
Workshop on Small Cell Lung Cancer in 1981, but
definitive answers could not be established (Bleehen
et al., 1983). Updated and more detailed data from
a number of these studies are now available (Table
VII) (Stevens et al., 1979; Fox et al., 1980; Kies et
al., 1982; Bunn et al., 1985; Souhami et al., 1984;
Perez et al., 1984; Smyth & Hansen, 1985). Whether
chemotherapy with or without thoracic irradiation
was employed did not result in significantly differ-
ent survival durations in the majority of the trials.
The combined modality therapy appeared to be
significantly better than chemotherapy alone in two
of the studies but further follow-up of these
preliminary data should be awaited before too
firm conclusions are drawn. The survival data and
especially the long-term results reported in the
present study are definitive while projected two-
year survival rates, such as those estimated in three
of the studies, may have a tendency to change with
further follow-up (Cohen, 1983). This tendency may
predominate in irradiated patients due to late
radiation toxicity as observed in this as well as
in other studies of long survivors (Catane et al.,
1981; Ellison et al., 1982). At present the total
available number of two-year survivors is still too
small to enable definite conclusions about a possible
advantageous role of chest irradiation in long-term
control of limited SCC.
The combined modality regimen employed in the
present trial resulted in marginally more complete
remissions and longer complete response durations
than when chemotherapy was used alone. In addition
a higher fraction of patients receiving combined
modality treatment was disease-free at autopsy.
These results were obtained at the expense of
extra haematologic toxicity in spite of an average
10% dose reduction, and the question arises
whether or not the same degree of disease control
could have been achieved with an equitoxic chemo-
therapy regimen. More intensive chemotherapy
would presumably result in more treatment related
deaths including a slightly increased risk of second-
ary leukaemia (Pedersen-Bjergaard et al., 1985;
Rieche, 1984), but the long-term results would not
be influenced by morbidity and mortality due to
irradiation pulmonary and pericardial fibrosis
(Ellison et al., 1982).
The radiotherapy regimen employed in the
present study was effective in controlling the
primary tumour as reflected by a significantly
reduced frequency of residual chest disease at
autopsy, but the efficacy was obtained at the cost
of a number of deaths in complete remission. The
present irradiation regimen was widely used at the
time the trial was planned. Thus, it was the current
treatment of potentially curable lung cancer at the
Mayo Clinic (Lee, 1983). The side effects of this
short course radiation regimen were compared to
those of a less intensive schedule, delivering 50Gy
in 15 fractions in 3 weeks plus 10 fractions in 2
weeks, with 2 weeks rest (Sealy et al., 1982). The
toxicity was acceptable in both treatment groups
and no significant differences were observed.
Knowledge about potentiation between irradiation
and chemotherapy has increased considerably during
the last decade and several of the irradiation
regimens listed in Table VII may therefore be more
appropriate for combined therapy. More long-term
results, especially from randomized trials, should be
accrued, however, before evaluation of advantages
versus disadvantages of the different regimens is
carried out.
It has been discussed whether radiotherapy
should be administered early or late in the treat-
ment course. A treatment policy of late irradiation
restricted to responders does not find support in
available data (Fox et al., 1980; Bunn et al., 1985)
(Table VII) and treatment of all patients concur-
rently with the first dose of chemotherapy or 4, 9 or
12 weeks later does not seem to result in major
differences. Late addition of the radiotherapy is,
however, associated with an often overlooked meth-
odologic enigma. If randomization is carried out on
the first day of chemotherapy, as it was in all trials
summarized in Table VII, the risk of accidentally
occurring differences between the treatment groups
will increase with time until initiation of radio-
therapy. About one fifth of the patients in the
British study (Souhami et al., 1984) thus did not
meet the criteria to receive radiotherapy at time of
reevaluation, 12 weeks after allotment, and in the
trial from the Southeastern Cancer Study Group
(Perez et al., 1984) 11% of the patients randomized
to receive chemotherapy alone and 5% of the
combined modality treated group either expired or
had disease progression before day 29 when chest
irradiation was initiated. This problem should be
avoided in future trials although retrospective
adjustments, as carried out in the present analysis,
may enable a more accurate evaluation of the effect,
ascribed to different efficacies of the investigated
treatment regimens.CHEMOTHERAPY+IRRADIATION IN SCC 15
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Based on the lack of a positive effect of chest
irradiation in the present trial we have since excluded
chest radiotherapy from the primary treatment of
patients with limited SCC. Subsequent controlled
trials at our institutions have resulted in com-
bination chemotherapy regimes which are more
efficacious than the present four agent combina-
tion (Qsterlind et al., 1982; Hansen et al., 1983).
Reintroduction of irradiation would therefore
depend on results of a new prospective controlled
trial. In contrast to the present one a new trial
would have the advantage of the current knowledge
of interactions between chemotherapy and irradia-
tion and of the availability of computerized radio-
therapy planning, both enabling a better control of
organ toxicity. Generally, however, it is obvious
that evaluation of new drugs and innovative ways
of using available drugs play a pivotal role for
major therapeutic progress ofthis early disseminating
disease.
Supported by grants from the Esper and Olga Boel
Foundation.
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